LOKALNI VODIČ ZA PRIMENU LEKOVA KOD PACIJENATA OBOLELIH OD COVID-a 19
LOKALNI VODIČ ZA PRIMENU LEKOVA KOD PACIJENATA SA COVID-om 19
Sažetak
Cilj. U Republici Srbiji do danas nije bilo vodiča za primenu lekova kod pacijenata obolelih od COVID-a 19 koji su autorizovani i publikovani u stručnoj ili naučnoj literaturi, ili su dostupni na zvaničnim internet stranicama Ministarstva zdravlja odnosno ustanova zdravstvenog karaktera. Cilj ovog rada je da prikaže lokalni vodič za primenu lekova kod pacijenata sa COVID-om 19, kao i postupak njegove izrade i usvajanja.
Metode. Predlog vodiča je izradila radna grupa na osnovu rezultata sistematskog pretraživanja medicinske literature i provere kvaliteta pronađenih publikacija iz kategorije “vodiči kliničke prakse”. Predlog radne grupe je razmatran i usvojen na sednicama Komisije za lekove i Komisije za kvalitet Univerzitetskog kliničkog centra Kragujevac.
Rezultati. Preporuke vodiča su gradirane prema tipu pacijenata, i sve imaju isti stepen, kao i isti kvalitet dokaza na kojima su zasnovane. Tipovi pacijenata su formirani prema težini oboljenja i potrebi za respiratornom potporom, kao i prema riziku za razvoj sekundarne bakterijske infekcije.
Zaključak. Lokalni vodič za primenu lekova kod pacijenata obolelih od COVID-a 19 je izrađen i usvojen u kratkom vremenskom roku, primarno zbog potrebe za njegovom hitnom primenom. Revizija ovog vodiča je planirana nakon 6 meseci od datuma njegovog usvajanja.
Reference
Smith AA, Akerson J, Danahey J, Dinh TNM, Porter PS Jr. COVID-19 drive-through testing survey: measuring the burden on healthcare workers. J Am Coll Emerg Physicians Open 2020; Oct 15:10.1002/emp2.12286. (doi: 10.1002/emp2.12286.2).
Wang B, Lai J, Yan X, Jin F, Yi B, An C, et al. COVID-19 Clinical trials registered worldwide for drug intervention: an overview and characteristic analysis. Drug Des Devel Ther 2020; 14: 5097108.
Varshneya M, Irurzun-Arana I, Campana C, Dariolli R, Gutierrez A, Pullinger TK, et al. Investigational treatments for COVID-19 may increase ventricular arrhythmia risk through drug interactions. CPT Pharmacomet Syst Pharmaco 2020; Nov 17. (doi: 10.1002/psp4.125734).
Takla M, Jeevaratnam K. Chloroquine, hydroxychloroquine, and COVID-19: systematic review and narrative synthesis of efficacy and safety. Saudi Pharm J 2020; Nov 13. (doi: 10.1016/j.jsps.2020.11.003).
Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Cheng VC-C, et al. Infectious Diseases Society of America Guidelines on the treatment and management of patients with COVID-19. Clin Infect Dis 2020; Apr 27: ciaa478. (doi: 10.1093/cid/ciaa478).
COVID-19 rapid guideline: antibiotics for pneumonia in adults in hospital. NICE guideline [NG173]. London: National Institute for Health and Care Excellence, 2020. (https://www.nice.org.uk/guidance/ng173/resources/covid19-rapid-guideline-antibiotics-for-pneumonia-in-adults-in-hospital-pdf-66141959536069).
COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. Bethesda: National Institutes of Health, 2020. (https://www.covid19treatmentguidelines.nih.gov/).
Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Inf Dis 2016; 63: e61-111.
Janković SM. Antiviral therapy of COVID-19. Scr Med 2020; 51: 131–3.
Korona virus COVID-19. Beograd: Ministarstvo zdravlja Republike Srbije, Institut za javno zdravlje Srbije „Dr Milan Jovanović Batut“, 2020. (https://covid19.rs/).
Vaughn VM, Gandhi T, Petty LA, et al. Empiric antibacterial therapy and community-onset bacterial co-infection in patients hospitalized with COVID-19: a multi-hospital cohort study. Clin Infect Dis 2020; Aug 21: ciaa1239. (doi: 10.1093/cid/ciaa1239).
American Academy of Family Physicians. Clinical practice guideline manual. Leawood: American Academy of Family Physicians, 2020. (https://www.aafp.org/family-physician/patient-care/clinical-recommendations/cpg-manual.html).